New from NCI |
Leading the Nation’s Progress against Cancer |
| | NCI’s investment in cancer research has led to lower rates of new cancers and cancer deaths. Learn more about NCI’s plan for continued progress against cancer from this chapter of the NCI Annual Plan & Budget Proposal for Fiscal Year 2021. |
Tandem Stem Cell Transplant for High-Risk Neuroblastoma
Read about results from a clinical trial that show that many children with advanced forms of neuroblastoma may benefit more from receiving two separate stem cell transplants as part of their treatment instead of one. |
Helping Parents Quit Smoking
Read about research that tested whether training pediatricians’ offices to provide smoking cessation treatment to parents during visits with their child’s doctor can help those parents quit smoking. |
To Treat Pancreatic Cancer, Mouse Study Suggests Changing Tumor Microbiome
Read about results from a new study that suggest that, for people with pancreatic cancer, the makeup of bacteria in their tumors may predict how long they live. |
New Drug Approved Based on Tumor Genetics Rather Than Cancer Type
The Food and Drug Administration (FDA) has approved entrectinib (Rozlytrek) for adults and adolescents aged 12 or older who have cancer with a specific genetic change, no matter what type of cancer they have.
|
No hay comentarios:
Publicar un comentario